Adipose tissue expandability: The metabolic problems of obesity may arise from the inability to become more obese

Biochemical Society Transactions

Volumn 36, Issue 5, 2008, Pages 935-940

  Tan, Chong Yew ^a   Vidal Puig, Antonio ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Adipose tissue; Expandability; Fat storage; Insulin resistance; Metabolism; Obesity

Indexed keywords

ADIPOCYTOKINE; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 4; GLITAZONE DERIVATIVE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INTERLEUKIN 6; LEPTIN; LIPOCALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOGENESIS; ADIPOSE TISSUE; BODY FAT; BODY MASS; CALORIC INTAKE; CELL DIFFERENTIATION; CONFERENCE PAPER; DIET RESTRICTION; DIET THERAPY; DRUG MECHANISM; ENERGY EXPENDITURE; EPIGENETICS; EXERCISE; FOOD INTAKE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; LIPODYSTROPHY; LIPOSUCTION; METABOLIC DISORDER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; WEIGHT REDUCTION;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BODY COMPOSITION; BODY CONSTITUTION; ENERGY INTAKE; ENERGY METABOLISM; HUMANS; MODELS, BIOLOGICAL; OBESITY;

EID: 53849143606     PISSN: 03005127     EISSN: None     Source Type: Journal    
DOI: 10.1042/BST0360935     Document Type: Conference Paper

References (61)

1. World Health Organization (2006) WHO Fact Sheet No, 311, WHO, Geneva, Switzerland
2. Ford, E.S., Williamson, D.F. and Liu, S. (1997) Weight change and diabetes incidence: findings from a national cohort of US adults. Am. J. Epidemiol. 146, 214-222
3. Phelan, S., Wadden, T.A., Berkowitz, R.I., Sarwer, D.B., Womble, L.G., Cato, R.K. and Rothman, R. (2007) Impact of weight loss on the metabolic syndrome. Int. J. Obes. 31, 1442-1448
4. Petersen, K.F. and Shulman, G.I. (2006) Etiology of insulin resistance. Am. J. Med. 119, S10-S16
5. Saltiel, A.R. (2001) You are what you secrete. Nat. Med. 7, 887-888
6. Scherer, P.F. (2006) Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55, 1537-1545
7. Sethi, J.K. and Vidal-Puig, A.J. (2007) Adipose tissue function and plasticity orchestrate nutritional adaptation. J. Lipid Res. 48, 1253-1262
8. Tontonoz, P., Hu, E. and Spiegelman, B.M. (1995) Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ. Curr. Opin. Genet. Dev. 5, 571-576
9. Tontonoz, P., Hu, E. and Spiegelman, B.M. (1994) Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147-1156
10. Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A.M., Saladin, R., Najib, J., Laville, M., Fruchart, J.C., Deeb, S. et al. (1997) The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. 272, 18779-18789
11. Hallakou, S., Doare, L., Foufelle, F., Kergoat, M., Guerre-Millo, M., Berthault, M.F., Dugail, I., Morin, J., Auwerx, J. and Ferre, P. (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46, 1393-1399
12. He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J.M. and Evans, R.M. (2003) Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U.S.A. 100, 15712-15717
13. Knouff, C. and Auwerx, J. (2004) Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocr. Rev. 25, 899-918
14. Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A. and Evans, R.M. (1999) PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585-595
15. Miles, P.D., Barak, Y., He, W., Evans, R.M. and Olefsky, J.M. (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J. Clin. Invest. 105, 287-292
16. Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T. et al. (1999) PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4, 597-609
17. Gray, S.L., Nora, E.D., Grosse, J., Manieri, M., Stoeger, T., Medina-Gomez, G., Burling, K., Wattler, S., Russ, A., Yeo, G.S. et al. (2006) Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor γ function (P465L PPARγ) in mice. Diabetes 55, 2669-2677
18. Tsai, Y.S., Kim, H.J., Takahashi, N., Kim, H.S., Hagaman, J.R., Kim, J.K. and Maeda, N. (2004) Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ. J. Clin. Invest. 114, 240-249
19. Garg, A. (2000) Lipodystrophies. Am. J. Med. 108, 143-152
20. Garg, A. (2004) Acquired and inherited lipodystrophies. N. Engl. J. Med. 350, 1220-1234
21. Simha, V. and Garg, A. (2006) Lipodystrophy: lessons in lipid and energy metabolism. Curr. Opin. Lipidol. 17, 162-169
22. Haque, W.A., Shimomura, I., Matsuzawa, Y. and Garg, A. (2002) Serum adiponectin and leptin levels in patients with lipodystrophies. J. Clin. Endocrinol. Metab. 87, 2395
23. Gavrilova, O., Marcus-Samuels, B., Graham, D., Kim, J.K., Shulman, G.I., Castle, A.L., Vinson, C., Eckhaus, M. and Reitman, M.L. (2000) Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105, 271-278
24. Oral, F.A,, Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A.J., DePaoli, A.M., Reitman, M.L., Taylor, S.I. et al. (2002) Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570-578
25. Petersen, K.F., Oral, E.A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G.W., DePaoli, A.M., Taylor, S.I., Gorden, P. and Shulman, G.I. (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109, 1345-1350
26. Savage, D.B. and O'Rahilly, S. (2002) Leptin: a novel therapeutic role in lipodystrophy. J. Clin. Invest. 109, 1285-1286
27. Matarasso, A. and Hutchinson, O.H. (2001) Liposuction. JAMA, J. Am. Med. Assoc. 285, 266-268
28. Giese, S.Y., Bulan, E.J., Commons, G.W., Spear, S.L. and Yanovski, J.A. (2001) Improvements in cardiovascular risk profile with large-volume liposuction: a pilot study. Plast. Reconstr. Surg. 108, 510-519
29. Klein, S., Fontana, L., Young, V.L., Coggan, A.R., Kilo, C., Patterson, B.W. and Mohammed, B.S. (2004) Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 350, 2549-2557
30. D'Andrea, F., Grella, R., Rizzo, M.R., Grella, E., Nicoletti, G., Barbieri, M. and Paolisso, G. (2005) Changing the metabolic profile by large-volume liposuction: a clinical study conducted with 123 obese women. Aesthetic Plast. Surg. 29, 472-478
31. Giugliano, G., Nicoletti, G., Grella, E., Giugliano, F., Esposito, K., Scuderi, N. and D'Andrea, F. (2004) Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women. Brit. J. Plast. Surg. 57, 190-194
32. Gonzalez-Ortiz, M., Robles-Cervantes, J.A., Cardenas-Camarena, L., Bustos-Saldana, R. and Martinez-Abundis, E. (2002) The effects of surgically removing subcutaneous fat on the metabolic profile and insulin sensitivity in obese women after large-volume liposuction treatment. Horm. Metab. Res. 34, 446-449
33. Robles-Cervantes, J.A., Martinez-Abundis, E., Gonzalez-Ortiz, M., Cardenas-Camarena, L., Hernandez-Salazar, E. and Olvera-Ozuna, R. (2007) Behavior of insulin sensitivity and its relation to leptin and tumor necrosis factor-α in obese women undergoing liposuction: 6-month follow-up. Obes. Surg. 17, 1242-1247
34. Martinez-Abundis, E., Molina-Villa, C.A., Gonzalez-Ortiz, M., Robles-Cervantes, J.A. and Saucedo-Ortiz, J.A. (2007) Effect of surgically removing subcutaneous fat by abdominoplasty on leptin concentrations and insulin sensitivity. Ann. Plast. Surg. 58, 416-419
35. Faust, I.M., Johnson, P.R. and Hirsch, J. (1977) Surgical removal of adipose tissue alters feeding behavior and the development of obesity in rats. Science 197, 393-396
36. Hong, Y.G., Kim, H.T., Seo, S.W., Chang, C.H., Rhee, E.J. and Lee, W.Y. (2006) Impact of large-volume liposuction on serum lipids in Orientals: a pilot study. Aesthetic Plast. Surg. 30, 327-332
37. Esposito, K., Giugliano, G., Giugliano, D., Arner, P., Busetto, L., Bassetto, F., Nolli, M.L. and Klein, S. (2004) Metabolic effects of liposuction: yes or no? N. Engl. J. Med. 351, 1354-1357
38. Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L.J. and DeFronzo, R.A. (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24, 710-719
39. Chavez-Tapia, N.C., Barrientos-Gutierrez, T., Tellez-Avila, F.I., Sanchez-Avila, F., Montano-Reyes, M.A. and Uribe, M. (2006) Insulin sensitizers in treatment of nonalcoholic fatty liver disease: systematic review. World J. Gastroenterol. 12, 7826-7831
40. Hallakou, S., Doare, L., Foufelle, F., Kergoat, M., Guerre-Millo, M., Berthault, M.F., Dugail, I., Morin, J., Auwerx, J. and Ferre, P. (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46, 1393-1399
41. Smith, S.R., de Jonge, L., Volaufova, J., Li, Y., Xie, H. and Bray, G.A. (2005) Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metab., Clin. Exp. 54, 24-32
42. Motoshima, H., Wu, X., Sinha, M.K., Hardy, V.E., Rosato, E.L., Barbot, D.J., Rosato, F.E. and Goldstein, B.J. (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J. Clin. Endocrinol. Metab. 87, 5662-5667
43. Muurling, M., Mensink, R.P., Pijl, H., Romijn, J.A., Havekes, L.M. and Voshol, P.J. (2003) Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. Metabolism 52, 1078-1083
44. Zierath, J.R., Ryder, J.W., Doebber, T., Woods, J., Wu, M., Ventre, J., Li, Z., McCrary, C., Berger, J., Zhang, B. and Moller, D.E. (1998) Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action. Endocrinology 139, 5034-5041
45. Nissen, S.E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471
46. Nathan, D.M. (2007) Rosiglitazone and cardiotoxicity: weighing the evidence. N. Engl. J. Med. 357, 64-66
47. Brun, R.P. and Spiegelman, B.M. (1997) PPARγ and the molecular control of adipogenesis. J. Endocrinol. 155, 217-218
48. Kim, J.Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M.E., Hofmann, S.M., Schraw, T., Durand, J.L., Li, H., Li, G. et al. (2007) Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117, 2621-2637
49. Karelis, A.D., Brochu, M. and Rabasa-Lhoret, R. (2004) Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 30, 569-572
50. Brochu, M., Tchernof, A., Dionne, I.J., Sites, C.K., Eltabbakh, G.H., Sims, E.A.H. and Poehlman, E.T. (2001) What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J. Clin. Endocrinol. Metab. 86, 1020-1025
51. Bonora, E., Kiechl, S., Willeit, J., Oberhollenzer, F., Egger, G., Targher, G., Alberiche, M., Bonadonna, R.C. and Muggeo, M. (1998) Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes 47, 1643-1649
52. Ferrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N. and Mingrone, G. (1997) Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J. Clin. Invest. 100, 1166-1173
53. Karelis, A.D., Faraj, M., Bastard, J.-P., St-Pierre, D.H., Brochu, M., Prud'homme, D. and Rabasa-Lhoret, R. (2005) The metabolically healthy but obese individual presents a favorable inflammation profile. J. Clin. Endocrinol. Metab. 90, 4145-4150
54. Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R., Ohannesian, J.P., Marco, C.C., McKee, L.J., Bauer, T.L. and Caro, J.F. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334, 292-295
55. Banks, W.A. (2001) Leptin transport across the blood-brain barrier: implications for the cause and treatment of obesity. Curr. Pharm. Des. 7, 125-133
56. Bullen, Jr, J.W., Bluher, S., Kelesidis, T. and Mantzoros, C.S. (2007) Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. Am. J. Physiol. Endocrinol. Metab. 292, E1079-E1086
57. Medina-Gomez, G., Gray, S.L., Yetukuri, L., Shimomura, K., Virtue, S., Campbell, M., Curtis, R.K., Jimenez-Linan, M., Blount, M., Yeo, G.S. et al. (2007) PPARγ2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3, e64
58. Maffeis, C., Silvagni, D., Bonadonna, R., Grezzani, A., Banzato, C. and Tato, L. (2007) Fat cell size, insulin sensitivity, and inflammation in obese children. J. Pediatr. 151, 647-652
59. Nair, K.S. (2005) Aging muscle. Am. J. Clin. Nutr. 81, 953-963
60. Slawik, M. and Vidal-Puig, A.J. (2006) Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res. Rev. 5, 144-164
61. Yetukuri, L., Katajamaa, M., Medina-Gomez, G., Seppanen-Laakso, T., Vidal-Puig, A. and Oresic, M. (2007) Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst. Biol. 1, 12